

P & T COMMITTEE MEETING COMMENT PERIOD

REQUEST TO PROVIDE COMMENT NOTICE REQUIREMENTS

Please refer to the Michigan P & T Committee Notice for Additional Information

The public comments agenda item of the Pharmacy and Therapeutics Committee meeting is for the purpose of providing an opportunity for interested parties to provide comment. In order to do so, a written notice forwarded through e-mail, fax or U S mail must be sent to the P&T Committee Chairperson.

This written notice to comment must include:

- your name,
- how you can be contacted (i.e., a phone number, address, and/or fax numbers),
- the organization you are representing,
- your relationship to the organization and topic (such your title/position with the organization, your participation as member of an organization's speakers bureau, researcher including who is sponsoring/supporting the research, etc as appropriate) and
- the topic area that you wish to comment on.

The request must be received at least 3 days before the meeting date.

To submit a request by fax, please submit to:

Michigan Pharmacy and Therapeutics Committee
Attention: Chairperson
Fax Number: 517-241-8135

To submit a request by mail, please send to:

Department of Community Health
Michigan Pharmacy and Therapeutics Committee Chairperson
Attention: Donna Hammel
P O Box 30479
Lansing, MI 48909-7979

To submit a request by e mail, please send to:

hammeld@michigan.gov

Please include “Request to Provide Comment at P&T Committee” in the subject line of your e mail.

WRITTEN MATERIALS

Written materials may be provided for committee members to supplement your comments. Unless forwarded electronically, three (3) copies are required initially although the Department may request additional copies.

P & T Committee Members have requested an opportunity to review such written materials in advance of the meeting. Materials should be forwarded to the above US mail address or e mail contact if available electronically and no later than one week before the scheduled meeting to enable the Department to provide this information to the committee members several days in advance of the meeting. Distribution of hand-outs and other materials will not be allowed during the public comment portion of the meeting.

GUIDELINES FOR PROVIDING COMMENT

1. The time on the agenda for each agenda item is limited. An individual’s comments to the committee are limited to 5 minutes in total.
2. Only one speaker “slot” will be available per meeting representing a single manufacturer or interest group. Within the allowable 5 minute time period, multiple speakers may share this “slot”.
3. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
4. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
5. Committee members will be provided with the list of speakers, the organization being represented (as applicable), speaker’s relationship to the organization or topic area and the topic as provided in the “request to comment”.
6. Topics for public comment will be limited to the new drugs being considered at the meeting or PDL classes being reviewed. Comments on classes for which “key questions” are to be discussed should be directed to the workgroup identified. Information on key questions may be directed to the workgroups through the P&T chairperson as indicated above.

